Serial Therapeutic and Antifungal Monitoring Protocol
NCT02163889
Bacterial Infections and Mycoses, Candidemia
Birmingham, Alabama, United States
View Trial DetailsNCT Number: NCT01752166
The purpose of this study is to validate clinical performance (i.e. estimated sensitivity and specificity) of the T2 Candida test on the T2 DX Instrument compared to blood culture results and/or known Candida positive status of prospectively collected and contrived (i.e. Candida-spiked) clinical specimens.
Looking for future studies?
Notify Me18 year–95 year
All sexes
Observational
University of Alabama at Birmingham, Birmingham, Alabama, United States
This study will prospectively collect and analyze whole blood T2 clinical research specimens and concomitant blood culture specimens from patients who have been referred for a blood culture per routine standard of care. Additional analysis of blinded, contrived (i.e. Candida spiked and un-spiked whole blood) specimens will be completed by study sites to augment the analysis of Candida positive blood specimens prospectively obtained from the study population.
The clinical performance of the T2 Candida test on the T2 Dx Instrument will be evaluated by calculating the:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Up to 19 hours post blood collection
Estimated specificity of the T2Candida test will be examined by comparing T2Candida test results from prospectively collected T2 clinical specimens to blood culture results from specimens that are culture negative for Candida and which have been collected at the same time and from the same anatomical location as the T2 specimens.
Time frame: Up to 19 hours post blood collection
Estimated sensitivity of the T2Candida test will be examined by comparing T2Candida test results to the known Candida positive status or Candida positive blood culture status of contrived specimens that have been spiked at clinically relevant concentrations of the target organisms and, where detected, to blood culture results from specimens that are culture positive for Candida and which have been collected at the same time and from the same anatomical location as the T2 specimens.
T2 Biosystems
Industry
Prospective Collection and Testing of Un-Spiked and Candida-Spiked Fresh Whole Blood Specimens From Patients Who Have Been Referred For a Diagnostic Blood Culture
Acronym: direcT2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02163889
Bacterial Infections and Mycoses, Candidemia
Birmingham, Alabama, United States
View Trial DetailsNCT01281345
Bacterial Infections and Mycoses, Candidemia
Chandigarh, Uttarakhand, India
View Trial DetailsNCT01525095
Bacterial Infections and Mycoses, Candidemia
Birmingham, Alabama, United States
View Trial DetailsNCT00113191
Bacterial Infections, Bacterial Infections and Mycoses
Birmingham, Alabama, United States
View Trial Details